(ALIF-B) AddLife (publ) - Ratings and Ratios
Medical Equipment, Consumables, Reagents, Diagnostics, Laboratory Supplies
ALIF-B EPS (Earnings per Share)
ALIF-B Revenue
Description: ALIF-B AddLife (publ)
AddLife AB (publ) is a Swedish company that provides equipment, consumables, and reagents to various industries, primarily healthcare, research, and pharmaceuticals, through its two main segments: Labtech and Medtech. The Labtech segment focuses on diagnostics, biomedical research, and laboratory analysis equipment, while the Medtech segment provides medical device products for various applications, including orthopedic, hospital consumables, and assistive technology.
The companys diverse product portfolio and geographic presence across Europe, with operations in multiple countries, including Sweden, the UK, Ireland, and Germany, contribute to its revenue growth. To evaluate the companys performance, key performance indicators (KPIs) such as revenue growth rate, gross margin, and operating margin can be analyzed. A high revenue growth rate and stable gross margin would indicate a strong market position.
From a financial perspective, AddLife AB (publ) has a market capitalization of 22.6 billion SEK, indicating a significant presence in the market. The companys price-to-earnings (P/E) ratio of 71.31 suggests that the stock may be overvalued, and a thorough analysis of the companys earnings growth prospects is necessary. Return on Equity (RoE) of 5.97% is relatively low, indicating that the company may not be generating sufficient returns on shareholder equity.
To further analyze the companys prospects, other KPIs such as Debt-to-Equity ratio, Interest Coverage ratio, and Cash Flow Conversion ratio can be examined. A low Debt-to-Equity ratio and high Interest Coverage ratio would indicate a healthy balance sheet, while a high Cash Flow Conversion ratio would suggest efficient operations.
ALIF-B Stock Overview
| Market Cap in USD | 2,443m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception |
ALIF-B Stock Ratings
| Growth Rating | 47.4% |
| Fundamental | 50.2% |
| Dividend Rating | 22.9% |
| Return 12m vs S&P 500 | -0.98% |
| Analyst Rating | - |
ALIF-B Dividends
| Dividend Yield 12m | 0.42% |
| Yield on Cost 5y | 0.57% |
| Annual Growth 5y | 0.00% |
| Payout Consistency | 76.8% |
| Payout Ratio | 27.2% |
ALIF-B Growth Ratios
| Growth Correlation 3m | -22.4% |
| Growth Correlation 12m | 68.1% |
| Growth Correlation 5y | -30.4% |
| CAGR 5y | 18.84% |
| CAGR/Max DD 3y | 0.31 |
| CAGR/Mean DD 3y | 1.19 |
| Sharpe Ratio 12m | 0.30 |
| Alpha | 0.00 |
| Beta | 0.990 |
| Volatility | 28.85% |
| Current Volume | 64.1k |
| Average Volume 20d | 59.4k |
| Stop Loss | 188 (-3%) |
| Signal | 0.72 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (337.0m TTM) > 0 and > 6% of Revenue (6% = 626.5m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 3.69pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -2.66% (prev -5.76%; Δ 3.10pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 1.16b > Net Income 337.0m (YES >=105%, WARN >=100%) |
| Net Debt (-253.0m) to EBITDA (578.0m) ratio: -0.44 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.93 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (121.9m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 37.79% (prev 37.25%; Δ 0.54pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 81.01% (prev 76.66%; Δ 4.35pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.14 (EBITDA TTM 578.0m / Interest Expense TTM 268.0m) >= 6 (WARN >= 3) |
Altman Z'' 0.36
| (A) -0.02 = (Total Current Assets 3.82b - Total Current Liabilities 4.10b) / Total Assets 12.75b |
| (B) 0.16 = Retained Earnings (Balance) 2.00b / Total Assets 12.75b |
| (C) -0.00 = EBIT TTM -38.0m / Avg Total Assets 12.89b |
| (D) 0.01 = Book Value of Equity 62.0m / Total Liabilities 7.48b |
| Total Rating: 0.36 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 50.16
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 4.03% = 2.02 |
| 3. FCF Margin 10.65% = 2.66 |
| 4. Debt/Equity 0.96 = 2.06 |
| 5. Debt/Ebitda 8.71 = -2.50 |
| 6. ROIC - WACC -8.76% = -10.96 |
| 7. RoE 6.48% = 0.54 |
| 8. Rev. Trend 76.50% = 5.74 |
| 9. EPS Trend 1.98% = 0.10 |
What is the price of ALIF-B shares?
Over the past week, the price has changed by +6.48%, over one month by +17.16%, over three months by -2.37% and over the past year by +17.56%.
Is AddLife (publ) a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ALIF-B is around 171.49 SEK . This means that ALIF-B is currently overvalued and has a potential downside of -11.56%.
Is ALIF-B a buy, sell or hold?
What are the forecasts/targets for the ALIF-B price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 196.5 | 1.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 190.4 | -1.8% |
ALIF-B Fundamental Data Overview
Market Cap SEK = 22.79b (22.79b SEK * 1.0 SEK.SEK)
CCE Cash And Equivalents = 253.0m SEK (last quarter)
P/E Trailing = 67.971
P/S = 2.1824
P/B = 4.3406
Beta = 1.546
Revenue TTM = 10.44b SEK
EBIT TTM = -38.0m SEK
EBITDA TTM = 578.0m SEK
Long Term Debt = 2.92b SEK (from longTermDebt, last quarter)
Short Term Debt = 2.12b SEK (from shortTermDebt, last quarter)
Debt = 5.03b SEK (Calculated: Short Term 2.12b + Long Term 2.92b)
Net Debt = -253.0m SEK (from netDebt column, last quarter)
Enterprise Value = 27.57b SEK (22.79b + Debt 5.03b - CCE 253.0m)
Interest Coverage Ratio = -0.14 (Ebit TTM -38.0m / Interest Expense TTM 268.0m)
FCF Yield = 4.03% (FCF TTM 1.11b / Enterprise Value 27.57b)
FCF Margin = 10.65% (FCF TTM 1.11b / Revenue TTM 10.44b)
Net Margin = 3.23% (Net Income TTM 337.0m / Revenue TTM 10.44b)
Gross Margin = 37.79% ((Revenue TTM 10.44b - Cost of Revenue TTM 6.50b) / Revenue TTM)
Tobins Q-Ratio = 444.7 (set to none) (Enterprise Value 27.57b / Book Value Of Equity 62.0m)
Interest Expense / Debt = 1.07% (Interest Expense 54.0m / Debt 5.03b)
Taxrate = 37.28% (151.0m / 405.0m)
NOPAT = -38.0m (EBIT -38.0m, no tax applied on loss)
Current Ratio = 0.93 (Total Current Assets 3.82b / Total Current Liabilities 4.10b)
Debt / Equity = 0.96 (Debt 5.03b / last Quarter total Stockholder Equity 5.27b)
Debt / EBITDA = 8.71 (Net Debt -253.0m / EBITDA 578.0m)
Debt / FCF = 4.53 (Debt 5.03b / FCF TTM 1.11b)
Total Stockholder Equity = 5.20b (last 4 quarters mean)
RoA = 2.64% (Net Income 337.0m, Total Assets 12.75b )
RoE = 6.48% (Net Income TTM 337.0m / Total Stockholder Equity 5.20b)
RoCE = -0.47% (Ebit -38.0m / (Equity 5.20b + L.T.Debt 2.92b))
RoIC = -0.73% (NOPAT -38.0m / Invested Capital 5.20b)
WACC = 8.03% (E(22.79b)/V(27.82b) * Re(9.66%)) + (D(5.03b)/V(27.82b) * Rd(1.07%) * (1-Tc(0.37)))
Shares Correlation 3-Years: 8.01 | Cagr: -0.04%
Discount Rate = 9.66% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.13% ; FCFE base≈929.6m ; Y1≈1.13b ; Y5≈1.86b
Fair Price DCF = 203.6 (DCF Value 23.88b / Shares Outstanding 117.3m; 5y FCF grow 23.05% → 3.0% )
EPS Correlation: 1.98 | EPS CAGR: -5.86% | SUE: -3.74 | # QB: False
Revenue Correlation: 76.50 | Revenue CAGR: 7.74%